trending Market Intelligence /marketintelligence/en/news-insights/trending/x4o1zbpmnatzdz2grjj5eq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca's blood disorder drug secures European approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca's blood disorder drug secures European approval

Cambridge, U.K.-based AstraZeneca PLC said its hyperkalemia treatment Lokelma secured marketing approval from the European Commission.

Hyperkalemia is a condition characterized by elevated potassium levels in the blood associated with cardiovascular, kidney and metabolic diseases.

The oral potassium-removing agent was initially given a positive opinion by the EMA in February 2017. However, the European Commission suspended its decision after some concerns relating to good manufacturing practices at the manufacturing site for the active substance and referred the matter back to the agency.

EMA later gave a positive nod to the treatment in January.

The approval is supported by three late-stage clinical trials where patients with hyperkalemia were treated for up to 12 months. The drug statistically demonstrated desired levels of potassium control in the blood of subjects.

Lokelma is also under review in the U.S., with a decision expected during the first half of 2018.